DNA Methylation of Neurodevelopmental, Stress-Response, Reward, and Opioid Pathway Genes: Sex Differences in…

Abstract

ObjectiveTo investigate sex-specific associations between DNA methylation (DNAm) of neurodevelopmental, stress-response, and dopaminergic pathway genes and need for pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS) among opioid-exposed newborns.

Study DesignBuccal swabs were collected at birth from 181 infants in the multi-site Child and Family Study (CAFS). DNAm was measured via pyrosequencing at CpG sites within promoter regions of neurodevelopmental (BDNF), stress-response (AVP, NR3C1, OXTR, FKBP5, SLC6A4), dopaminergic (DRD2, DRD4), and opioid signaling (OPRM1) genes. Need for pharmacological treatment for NOWS was obtained from medical records. We estimated robust linear regression models to investigate sex-specific associations of DNAm and need for NOWS treatment. Estimated marginal means quantified sex-specific DNAm differences by treatment status.

ResultsAfter correction for multiple testing, five CpG sites within DRD4 were significantly associated with need for pharmacological treatment, with four sites showing higher DNAm in treated infants and one showing lower DNAm. Significant sex-specific associations were identified within DRD4 and AVP.

ConclusionsEpigenetic variation across multiple biological pathways contributes to variability in NOWS severity among infants with prenatal opioid exposure. The relationship between epigenetic variation and need for NOWS treatment may vary depending on infant sex.

Neurodevelopmental Trajectories and Neurodevelopmental Disorders Following Neonatal Intracranial Hemorrhage: A Long-Term Follow-Up Study and Analysis of Influencing Factors
Su Lin, Ru Yu, Zhiyong Ding +1
Actas Españolas de Psiquiatría15 Oct 2026Peer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsPMC
Neurodevelopmental Outcomes of Very Preterm Infants Who Underwent Neonatal Gastrointestinal Surgery: A Single-Center Retrospective Cohort Study
Joo Hi Kim, Sungbo Shim, Ching-yu Lin +8
Yonsei Medical Journal8 Sep 2026Peer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
Cord blood metabolic network profiles link prenatal rare earth element exposure to neurodevelopmental delay in 2-year-old children
Ya Xie, Lin Qiu, Xingjie Fang +10
BMC Medicine15 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Pharmacology & toxicologyCrossref
Preconception, prenatal and postnatal exposure to gaseous air pollutants (NO2, O3) and neurodevelopmental disorders in children among Medicaid recipients: a national cohort study
Wanyu Huang, Krista F. Huybrechts, Sonia Hernandez-Diaz +10
Environmental research21 Jul 2026Peer-reviewedLicence not statedFull text1 citedPharmacology & toxicologyPMC
Clinical and multi-omics characterisation of early neurodevelopmental disorders associated with critical congenital heart disease: the prospective cohort CATAMARAN neonatal study protocol
Oscar Werner, Véronique Ferchaud-Roucher, Matilde Karakachoff +34
BMJ Open8 Sep 2026Peer-reviewedCC BYFull textEpidemiology & public healthHAL

Cite

BibTeX RIS

BibTeX

@misc{vasquez2026methylation,
  title = {{DNA Methylation of Neurodevelopmental, Stress-Response, Reward, and Opioid Pathway Genes: Sex Differences in Infants with Neonatal Opioid Exposure}},
  author = {A. Aragon Vasquez and M. Camerota and M. G. Coyle and E. D. Conradt and B. M. Lester},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.28.26364198},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.28.26364198v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - DNA Methylation of Neurodevelopmental, Stress-Response, Reward, and Opioid Pathway Genes: Sex Differences in Infants with Neonatal Opioid Exposure
AU  - A. Aragon Vasquez
AU  - M. Camerota
AU  - M. G. Coyle
AU  - E. D. Conradt
AU  - B. M. Lester
PY  - 2026
DA  - 2026/09/28
PB  - medRxiv
DO  - 10.64898/2026.09.28.26364198
UR  - https://www.medrxiv.org/content/10.64898/2026.09.28.26364198v1
AB  - ObjectiveTo investigate sex-specific associations between DNA methylation (DNAm) of neurodevelopmental, stress-response, and dopaminergic pathway genes and need for pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS) among opioid-exposed newborns.  Study DesignBuccal swabs were collected at birth from 181 infants in the multi-site Child and Family Study (CAFS). DNAm was measured via pyrosequencing at CpG sites within promoter regions of neurodevelopmental (BDNF), stress-response (AVP, NR3C1, OXTR, FKBP5, SLC6A4), dopaminergic (DRD2, DRD4), and opioid signaling (OPRM1) genes. Need for pharmacological treatment for NOWS was obtained from medical records. We estimated robust linear regression models to investigate sex-specific associations of DNAm and need for NOWS treatment. Estimated marginal means quantified sex-specific DNAm differences by treatment status.  ResultsAfter correction for multiple testing, five CpG sites within DRD4 were significantly associated with need for pharmacological treatment, with four sites showing higher DNAm in treated infants and one showing lower DNAm. Significant sex-specific associations were identified within DRD4 and AVP.  ConclusionsEpigenetic variation across multiple biological pathways contributes to variability in NOWS severity among infants with prenatal opioid exposure. The relationship between epigenetic variation and need for NOWS treatment may vary depending on infant sex.
ER  -

Abstract

Related

Cite